ACE1702 (anti-HER2 NK cells) and anti-HER2-CAR [chimeric antigen receptor]-macrophages are cell therapies being investigated in first-in-human phase I clinical trials in all solid tumours, including NSCLC with HER2 OE (NCT04319757, NCT04660929). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.